Video: Using Inhalers and Puffers in Asthma

Article

A clinical nurse consultant demonstrates best practices for inhalers and puffers, with an emphasis on pediatric asthma patients.

A clinical nurse consultant demonstrates best practices for inhalers and puffers, with an emphasis on pediatric asthma patients.

 

Recent Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
Direct Mail to Older Adults at Risk for Pneumococcal Disease Improves Vaccination Rates / image credit ©Kateryna_Kon/stock.adobe.com

Direct Mail to Older Adults at Risk for Pneumococcal Disease Improves Vaccination Rates

Grace Halsey
April 2nd 2025
Article

A mail campaign targeting adults with chronic conditions as well as their GPs increased the number receiving at least 1 shot by 9.5 percentage points.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose / image credit: ©New Africa/AdobeStock

Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose

Sydney Jennings
March 20th 2025
Article

Your daily dose of the clinical news you may have missed.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

FDA Accepts Depemokimab BLA for Asthma and Chronic Rhinosinusitis with Nasal Polyps

FDA Accepts Depemokimab BLA for Asthma and Chronic Rhinosinusitis with Nasal Polyps

Patient Care Editorial Staff
March 6th 2025
Article

The FDA set the Prescription Drug User Fee Act (PDUFA) date for December 16, 2025.

Dupilumab Shows Efficacy and Safety in COPD With Type 2 Inflammation: AAAAI 2025

Dupilumab Shows Efficacy and Safety in COPD With Type 2 Inflammation: AAAAI 2025

Patient Care Editorial Staff
March 6th 2025
Article

Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.

© 2025 MJH Life Sciences

All rights reserved.